Clinical progress note: ACC/AHA/HFSA 2022 heart failure guideline pearls for hospitalists.
Clinical progress note: ACC/AHA/HFSA 2022 heart failure guideline pearls for hospitalists.
复制标题
临床进展说明：ACC/AHA/HFSA 2022 住院医生心力衰竭指南珍珠。
DOI：
10.1002/jhm.13250
复制
发表时间：
2024
影响因子：
2.6
通讯作者：
Anderson,MelL
中科院分区：
文献类型：
--
作者：
Khazanie,Prateeti;Anderson,MelL
心力衰竭（HF）是美国住院和医疗保健费用的主要原因。1约25%因HF恶化住院的患者在出院后30天内再次住院或死亡。2住院医师处于HF住院患者护理的最前沿，住院患者开始疾病改善药物治疗、护理过渡、出院前药物核对和教育以及出院后早期随访是质量改善干预的关键时间点。3.医学治疗和临床干预的最新进展极大地改变了HF护理，因此住院医师必须彻底了解这些实践变化。2022年美国心脏病学会（ACC）/美国心脏协会（AHA）/美国心力衰竭学会（HFSA）HF指南4涉及多种重要的医学治疗、器械干预和护理过程。本临床进展说明强调了与成人住院医师相关的主要建议，以指导对这一高危人群的护理，并加强本指南向临床实践的转化。
Heart failure (HF) is a leading cause of hospitalization and healthcare costs in the United States. 1 Approximately 25% of patients hospitalized for worsening HF are rehospitalized or die within 30 days of discharge. 2 Hospitalists are at the forefront of care for patients hospitalized with HF, with inpatient initiation of disease‐modifying medical therapies, transitions of care, predischarge medication reconciliation and education, and early postdischarge follow‐up as critical timepoints for quality improvement interventions. 3 Recent advances in medical therapies and clinical interventions have dramatically changed HF care, making it imperative that hospitalists have a thorough understanding of these practice changes. The 2022 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) HF Guideline 4 addressed multiple important medical therapies, device interventions, and processes of care. This clinical progress note highlights the major recommendations relevant to adult hospitalists to guide care of this high‐risk population and to enhance the translation of this guideline into clinical practice.